Get started
Author

Mark Oette

Computational methods for the design of effective therapies against drug resistant HIV strains
2005 · N. Beerenwinkel, T. Sing, et al. · Computer applications in the biosciences · 102
PDF
Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance Testing
2006 · Mark Oette, Rolf Kaiser, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 101
Deutsch‐Österreichische S2k‐Leitlinie: anale Dysplasien und Analkarzinome bei HIV‐Infizierten: Prävention, Diagnostik und Therapie
2015 · Stefan Esser, Alexander Kreuter, et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 84
Lipodystrophy Syndrome and Self-Assessment of Well-Being and Physical Appearance in HIV-Positive Patients
2002 · Mark Oette, Petra Juretzko, et al. · AIDS Patient Care and STDs · 77
Survival of AIDS ‐related diffuse large B‐cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort
2014 · Philipp Schommers, Marcus Hentrich, et al. · British Journal of Haematology · 76
Compensatory Mutations at the HIV Cleavage Sites P7/P1 and P1/P6-Gag in Therapy-Naive and Therapy-Experienced Patients
2006 · Jens Verheyen, Elena Litau, et al. · Antiviral Therapy · 76
Psychomotor Slowing in Hepatitis C and HIV Infection
2004 · Hans-J??rgen von Giesen, Tobias Heintges, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 63
Prevalence of oral lesions and periodontal diseases in HIV-infected patients on antiretroviral therapy.
2005 · Arne Kroidl, A Schaeben, et al. · PubMed · 58
Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study
2006 · M. Hentrich, L. Maretta, et al. · Annals of Oncology · 54
Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure
2009 · Melanie Balduin, Mark Oette, et al. · Journal of Clinical Virology · 52
Trends of prevalence of primary HIV drug resistance in Germany
2007 · A. Sagir, M. Oette, et al. · Journal of Antimicrobial Chemotherapy · 49
PDF
Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R
2019 · Nadine Lübke, Björn Jensen, et al. · New England Journal of Medicine · 46
Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study
2018 · Philipp Schommers, Daniel Gillor, et al. · Haematologica · 45
PDF
Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)
2013 · J. Thoden, A. Potthoff, et al. · Infection · 43
PDF
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study
2011 · Mattia C. F. Prosperi, Nicola Mackie, et al. · Journal of Antimicrobial Chemotherapy · 41
PDF
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals
2000 · Jürgen K. Rockstroh, Frank Bergmann, et al. · AIDS · 38
Torque Teno Virus plasma level as novel biomarker of retained immunocompetence in HIV-infected patients
2021 · L. Schmidt, B.-E. O. Jensen, et al. · Infection · 36
PDF
Treatment of Spondylodiscitis in Human Immunodeficiency Virus-Infected Patients
2009 · R Sobottke, K Zarghooni, et al. · Spine · 35
Characterization of Novel HIV Drug Resistance Mutations Using Clustering, Multidimensional Scaling and SVM-Based Feature Ranking
2005 · Tobias Sing, Valentina Svicher, et al. · Lecture notes in computer science · 35
Proviral DNA as a Target for HIV-1 Resistance Analysis
2015 · Nadine Lübke, Veronica Di Cristanziano, et al. · Intervirology · 34
Hodgkin lymphoma is as common as non‐ H odgkin lymphoma in HIV ‐positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study
2014 · C Hoffmann, M Hentrich, et al. · HIV Medicine · 32
Long‐term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy
2002 · M Lichterfeld, HD Nischalke, et al. · HIV Medicine · 30
Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.
2004 · Mark Oette, R Kaiser, et al. · PubMed · 29
Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients
2010 · Stefan Reuter, Mark Oette, et al. · Medical Microbiology and Immunology · 28
S1 Guidelines for the Kaposi Sarcoma
2022 · Stefan Esser, Helmut Schöfer, et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 25
PDF
Works count: 122
Citation count: 1,809
H-index: 25
I10-index: 48
Year
Topic
Type